> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Touts New Tagrisso Data
- URL: https://www.fdaweb.com/astrazeneca-touts-new-tagrisso-data/
- Published: 2025-03-26T12:00:00.000Z
- Updated: 2026-09-14T14:56:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158893

AstraZeneca says [new study data](https://www.astrazeneca.com/media-centre/press-releases/2025/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings.html?ref=fdaweb.com) on Tagrisso (osimertinib) show an “improved overall survival trend” in patients with epidermal growth factor receptor-mutated non-small cell lung cancer. Results from the Phase 3 LAURA trial demonstrated that patients on Tagrisso lived a median 58.8 months compared with 54.1 months on placebo, despite 78% of placebo patients moving to Tagrisso after progression, the company says.

AstraZeneca also says data from the Phase 2 SAVANNAH and ORCHARD trials showed that adding savolitinib or datopotamab deruxtecan-dlnk at the time of disease progression can help prolong patients’ responses to treatment.